Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA seeks public input on adulteration

This article was originally published in The Gold Sheet

Executive Summary

FDA plans to hold a public workshop this spring to begin the task of combating profit-motivated adulteration of regulated products. The workshop, with date and location to be announced shortly, will allow government agencies, industry stakeholders, academics and the public to advise FDA on issues surrounding fake ingredients and adulterated products, according to FDA Deputy Commissioner for Policy Randall Lutter. At a meeting of FDA's Science Board Feb. 24 in Gaithersburg, Md., Lutter acknowledged that firms may not alert regulators to adulteration "if they're able to control these problems at a relatively early stage," since raising flags could be "embarrassing," he said. Current FDA regulations require notifications about adulterations only when affected products have been shipped, a policy that members of Congress have criticized while discussing the agency's ongoing response to contaminated peanut ingredients. Lutter said the agency is striving to solicit information in both public and confidential forums. To collect information confidentially, FDA Feb. 23 launched a Web site that allows anonymous reporting of adulteration of regulated products to the agency's Office of Criminal Investigations at

You may also be interested in...

Health And Wellness Trademark Review 19 January, 2021

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Europe's CBD Market In 2020: Narcotic Vs Novel Food

INFOGRAPHIC: An interactive timeline of selected HBW Insight coverage of the growing European CBD dietary supplements market in 2020. The timeline covers the main events of a rollercoaster 12 months, including the European Commission’s indecision on whether to classify CBD as narcotic or novel food and how the path forward became clear in the UK.

Servier and MiNA Target Neurodegenerative Disease With Novel RNA Therapy

Already partnering with AZ and Boehringer Ingelheim in liver targets, the UK biotech sees potential to hit ‘undruggable’ CNS targets as well.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts